The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The lender is planning a new EUR400 million share buyback and ...

The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The lender is planning a new EUR400 million share buyback and ...

The sales of connected cars are expected to rise due to increasing consumer demand for enhanced in-car experiences, improved ...